Compare Stocks

→ Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$0.99 -5.7%	$1.31	$0.93 ▼ $6.44	$4.39M	1.45	16,249 shs	24,369 shs
MOHO ECMOHO	$0.01	$0.01	$0.08 ▼ $0.89	$381K	0.83	4.07 million shs	242,736 shs
UNCY Unicycive Therapeutics	$1.12	$1.33	$0.47 ▼ $1.82	$42.12M	2.72	446,157 shs	168,641 shs
XCUR Exicure	$0.50	$0.60	$0.36 ▼ $1.50	$4.33M	1.31	39,627 shs	6,709 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	-5.34%	-10.00%	-22.66%	-54.17%	-67.67%
MOHO ECMOHO	0.00%	0.00%	0.00%	0.00%	0.00%
UNCY Unicycive Therapeutics	0.00%	+8.74%	-18.25%	+20.07%	-9.68%
XCUR Exicure	0.00%	+0.18%	-10.54%	-7.90%	-53.61%

Gold Mania (Ad)

Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).

See his free reveal right here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MOHO ECMOHO	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	3.1869 of 5 stars	3.5	3.0	0.0	0.0	4.1	2.5	0.6
XCUR Exicure	3.4437 of 5 stars	0.0	5.0	0.0	4.7	2.8	1.7	1.9

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A
MOHO ECMOHO	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	3.00	Buy	$5.30	373.21% Upside
XCUR Exicure	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest MOHO, XCUR, DRUG, and UNCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2024	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$3.00
4/4/2024	UNCY Unicycive Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$9.00
4/1/2024	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.50
3/14/2024	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.50
3/5/2024	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.50
2/14/2024	UNCY Unicycive Therapeutics	Noble Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$6.00

(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$1.30 per share	N/A
MOHO ECMOHO	$130.75M	0.00	N/A	N/A	$0.95 per share	0.01
UNCY Unicycive Therapeutics	$680K	61.95	N/A	N/A	($0.11) per share	-10.18
XCUR Exicure	$28.83M	0.15	N/A	N/A	$3.00 per share	0.17

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRUG Bright Minds Biosciences	-$5.47M	-$1.31	N/A	∞	N/A	N/A	-91.83%	-83.54%	5/20/2024 (Estimated)
MOHO ECMOHO	-$55.65M	-$1.40	N/A	∞	N/A	-42.57%	-76.43%	-40.85%	N/A
UNCY Unicycive Therapeutics	-$30.54M	-$1.55	N/A	N/A	N/A	N/A	N/A	-96.37%	5/21/2024 (Estimated)
XCUR Exicure	-$2.58M	$1.68	0.30	∞	N/A	N/A	N/A	N/A	7/12/2024 (Estimated)

Latest MOHO, XCUR, DRUG, and UNCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/28/2024	Q4 2023	UNCY Unicycive Therapeutics	-$0.18	-$0.16	+$0.02	-$0.16	N/A	N/A
2/12/2024	Q1 2024	DRUG Bright Minds Biosciences	N/A	-$0.32	-$0.32	-$0.32	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
MOHO ECMOHO	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRUG Bright Minds Biosciences	N/A	8.01	8.01
MOHO ECMOHO	N/A	1.36	1.02
UNCY Unicycive Therapeutics	N/A	0.76	0.76
XCUR Exicure	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
DRUG Bright Minds Biosciences	40.52%
MOHO ECMOHO	1.71%
UNCY Unicycive Therapeutics	40.42%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
DRUG Bright Minds Biosciences	42.66%
MOHO ECMOHO	N/A
UNCY Unicycive Therapeutics	42.00%
XCUR Exicure	3.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
DRUG Bright Minds Biosciences	N/A	4.43 million	2.54 million	Not Optionable
MOHO ECMOHO	455	30.49 million	N/A	Not Optionable
UNCY Unicycive Therapeutics	12	37.61 million	21.81 million	Not Optionable
XCUR Exicure	7	8.65 million	8.31 million	Not Optionable

MOHO, XCUR, DRUG, and UNCY Headlines

Source	Headline
	Exicure, Inc. (NASDAQ:XCUR) Short Interest Update americanbankingnews.com - April 28 at 1:34 AM
	Exicure faces Nasdaq non-compliance over delayed filing investing.com - April 24 at 5:47 PM
	Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K businesswire.com - April 22 at 4:01 PM
	Exicure gets grant for liposomal particles for gene regulation with spherical geometry pharmaceutical-technology.com - April 18 at 9:05 AM
	Exicure Stock (NASDAQ:XCUR), Short Interest Report benzinga.com - February 22 at 7:55 AM
	Exicure inks licensing deal for one of its remaining therapies chicagobusiness.com - February 12 at 7:43 AM
	Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session benzinga.com - February 6 at 2:15 PM
	Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket msn.com - February 6 at 9:44 AM
	Exicure Inc Announces Licensing Patents for Therapeutic Advancement msn.com - February 6 at 9:15 AM
	Exicure, Inc. and Bluejay Therapeutics Inc. Enter… pharmiweb.com - February 5 at 10:23 PM
	Exicure, Bluejay Therapeutics Enter Patent License Agreement to Develop Hepatitis Treatment marketwatch.com - February 5 at 5:22 PM
	Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis finance.yahoo.com - February 5 at 5:22 PM
	Best Undervalued Stocks for February 2024 msn.com - February 1 at 1:04 PM
	Exicure, Inc. (XCUR) Stock Price, News, Quote & History - Yahoo Finance ca.finance.yahoo.com - December 16 at 8:49 AM
	Why Is Exicure (XCUR) Stock Up 57% Today? investorplace.com - December 8 at 10:01 AM
	Exicure: Nonreliance On Previously Issued Financial Statements Or A Related Audit Report Or Completed Interim Review cbonds.com - December 3 at 8:28 AM
	Exicure receives Nasdaq delinquency notice on late filing of its form 10-Q msn.com - November 28 at 5:18 PM
	Exicure Inc XCUR morningstar.com - November 9 at 1:25 PM
	Lacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price Drop finance.yahoo.com - August 29 at 7:04 AM
	Exicure names new CEO, CFO, directors in wake of resignations msn.com - August 23 at 4:05 PM
	Exicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022) finance.yahoo.com - August 15 at 7:28 AM
	Exicure: Substantial Financing Needed to Continue Operations marketwatch.com - August 11 at 5:38 PM
	Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update businesswire.com - August 11 at 5:38 PM
	Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update finance.yahoo.com - July 14 at 6:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Stocks Leading the U.S. Agriculture Comeback
April 26, 2024 10:10 AM
View 3 Stocks Leading the U.S. Agriculture Comeback
How to Use Put Debit Spreads to Profit From Falling Stocks
April 26, 2024 9:30 AM
View How to Use Put Debit Spreads to Profit From Falling Stocks
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 9, 2024 6:07 AM
View Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
April 22, 2024 6:05 AM
View Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Cannabis Stocks: Game-Changing Catalyst for the Sector?
May 3, 2024 7:00 AM
View Cannabis Stocks: Game-Changing Catalyst for the Sector?

All Headlines

Company Descriptions

Bright Minds Biosciences

NASDAQ:DRUG

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

ECMOHO

NASDAQ:MOHO

ECMOHO Limited, an investment holding company, operates as an integrated solution provider in the health and wellness market. The company offers health supplements and food, mother and child care products, personal care products, and household healthcare equipment and cleaning products. It sells its products through flagship stores of its brand partners, self-operated branded stores on third-party e-commerce platforms; and other small and medium-sized online and offline retailers. The company is also involved in the provision of bonded area warehousing; online store operating services; and promotion and marketing services to its brand partners and other brand customers. It serves consumers and retailers. The company was founded in 2011 and is headquartered in Shanghai, the People's Republic of China.

Unicycive Therapeutics

NASDAQ:UNCY

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Exicure

NASDAQ:XCUR

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial